Key result
Serum IgA-IgM NMDAR antibodies are linked to ~170% higher odds of acute stroke.
Why the study?
Are NMDAR-Abs more frequent in acute stroke patients compared to controls, and do they affect clinical outcomes?
Meta-Analysis
Are NMDAR-Abs more frequent in acute stroke patients compared to controls, and do they affect clinical outcomes?
Answers are grounded in this paper and cite their sources.
Serum IgA/IgM NMDAR-Abs are more frequent in acute stroke patients compared to controls, though they do not appear to significantly affect clinical outcomes.
Background Antibodies against neuronal surface antigens (NSA-Abs), particularly against the NMDA receptor (NMDAR-Ab), have been reported in acute stroke patients (ASP). However, their role in stroke is far from being understood. Methods We conducted a systematic review and meta-analysis to investigate: 1) the frequency of NSA-Abs in patients with acute stroke compared to controls; 2) the de novo appearance of NSA-Abs after stroke; and 3) their effects on the clinical outcome. Results We included nine studies in the qualitative analysis and seven in the quantitative analysis. Analyses were restricted to NMDAR-Abs due to the lack of data about other NSA-Abs. Considering only studies that adopted a cell-based assay, IgA-IgM NMDAR-Abs isotypes (but not the IgG) were found more frequently in patients with acute stroke (OR 2.69, 95% CI 2.00–3.62, I 2 = 4%). There was no de novo NMDAR-Abs formation after stroke. There was no statistical difference in mean discharge/day–7 NIHSS (SMD 0.21, 95% CI -1.10–1.52, I2 = 84%) and 3–12-month mRS (SMD 0.38, 95% CI -0.56-1.32, I2 = 78%) between patients with stroke with and without NMDAR-Abs seropositivity. Conclusions Serum IgA/IgM NMDAR-Abs are more frequent in patients with stroke than controls. Due to several methodological issues, these findings should be interpreted cautiously. Additional, methodologically robust studies are needed to clarify the prevalence and significance of NMDAR-Abs in patients with stroke. Systematic review registration https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022241278#:~:text=https%3A//www.crd.york.ac.uk/prospero/display_record.php%3FID%3DCRD42022241278 , identifier CRD42022241278.
No takes yet. Share an insight, caveat, or question.
Paolucci et al. (2025) conducted a meta-analysis in acute stroke. IgA-IgM NMDAR-Abs isotypes vs. controls was evaluated on frequency of IgA-IgM NMDAR-Abs in patients with acute stroke (OR 2.69, 95% CI 2.00-3.62). Serum IgA-IgM NMDAR-Abs isotypes were found more frequently in patients with acute stroke compared to controls.
Synapse has enriched 10 related papers. Consider them for comparative context: